Anzeige
Mehr »
Samstag, 02.08.2025 - Börsentäglich über 12.000 News
Die Welt unter Strom: Wie Kupfer zum strategisch wichtigsten Metall der Erde wurde
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
180 Leser
Artikel bewerten:
(1)

MMJ International Holdings: Is DEA Administrator Terry Cole Just Another Anti Marijuana Crooner in A Suit? Or A Cannabis Policy Reformer

Newly confirmed DEA Administrator Terrance Cole faces a defining choice: Will he break ranks with the agency's deeply entrenched anti-cannabis cabal-or will he become just another DEA figurehead parroting the same tired "gateway drug" propaganda while Americans suffer, science stalls, and corruption thrives?

The public, the scientific community, and thousands of patients are watching-and the window for Cole to make a meaningful impact is rapidly closing.

WASHINGTON, D.C. / ACCESS Newswire / August 1, 2025 / The U.S. Drug Enforcement Administration (DEA) has declared war-not on drug cartels, not on fentanyl traffickers, but on science, patients, and any company bold enough to follow the law. And the proof is now overwhelming.

At the center of this disgrace are five names that should live in DEA regulatory infamy:

Anne Milgram's tenure as Administrator of the U.S. Drug Enforcement Administration will be remembered not for advancing science or protecting public health-but for perpetuating outdated ideology and obstructing life-saving cannabis research.

Thomas Prevoznik, the DEA's entrenched Assistant Administrator, whose retirement cannot come soon enough;

Matthew Strait, the DEA's policy Administrator who's legacy is one of regression-marked by bureaucratic sabotage, scientific censorship, and a failure to uphold the DEA's own mission to ensure an adequate and uninterrupted supply of controlled substances for medical and scientific purpose;

Aarathi Haig, an DEA lawyer whose contempt for due process and disregard for constitutional limits has become the stuff of legal nightmares; and

John "McLooney" Mulrooney, the now-retired Chief Administrative Law Judge whose kangaroo court was finally exposed by the U.S. Supreme Court as an unconstitutional charade.

The Scientific Crime: Blocking FDA-Authorized Cannabis Research

MMJ BioPharma Cultivation-a federally compliant pharmaceutical company developing cannabis-based medicines for Huntington's Disease and Multiple Sclerosis-has spent seven years and millions of dollars navigating the DEA's supposed "research licensing" process.

The company secured:

  • FDA Orphan Drug Designation

  • Two Active INDs

  • An FDA-inspected facility

  • Partnerships with European pharmaceutical suppliers

And yet the DEA said "no."

Why?

Because MMJ did not have a "bona fide supply agreement" (BFSA) with a DEA-registered Schedule I researcher-a requirement that did not even exist when MMJ applied in 2018. But wait MMJ realy had the agreement however the DEA just misplaced it, hmmmm.

This is classic regulatory sabotage.

The "Catch-22" That Kills Innovation

The BFSA requirement, which the DEA now uses as a pretext to deny applications, creates a legal paradox:

You can't get a registration without a supply agreement.
You can't get a supply agreement without a registration, and even if you have one we will bury it so no one knows.

This isn't policy. It's a weaponized bureaucratic chokehold designed to kill innovation and protect a cartel of fake registrants who grow nothing, contribute nothing, and do nothing.

Contaminated Cannabis, No Accountability

While MMJ's pharmaceutical-grade capsules sit in legal limbo, the DEA has allowed contaminated, mold-infested, pesticide-laced cannabis to flood state markets unchecked.

The scandal in Massachusetts-where Assured Testing Laboratories falsified safety reports and exposed thousands to unsafe cannabis-should have triggered a national emergency.

Instead?

Not a single DEA action.
No recall. No enforcement. No accountability.

Where was Prevoznik? Sitting in his office rubber-stamping rejections of legitimate researchers while Americans were poisoned.

Where was Haig? Filing smug legal briefs pretending that denying science serves the public interest.

Where was Mulrooney? Retiring quietly, leaving behind a legal dumpster fire that even the DOJ now refuses to defend.

Constitutional Collapse: Axon, Jarkesy, and the End of DEA's ALJ Scam

Let's be clear: the DEA's internal "court" system is dead. The Supreme Court ruled in Axon v. FTC and Jarkesy v. SEC that agencies cannot act as investigator, prosecutor, judge, and executioner. But that's exactly what DEA did for years-until now.

Haig, in her July 25, 2025, response, openly admitted that constitutional questions were "legally meritless." In reality, they were so legally valid the Department of Justice dropped its own defense of the ALJ process entirely.

She lied. And the courts proved it.

MMJ Fights Back: The Legal Case They Can't Bury

MMJ's formal legal exceptions-filed July 3, 2025-lay bare the unconstitutional delays, structural bias, and retroactive rules that define the DEA's obstruction. And DEA's weak reply, written by Haig and backed by nothing but circular logic and selective precedent, proves they have no case-only power they're desperately clinging to.

Even Haig's citation of Craker v. DEA fails: that case never addressed companies like MMJ with active FDA trials and pending INDs.

This isn't Craker. This is cancer patients waiting. This is Huntington's Disease research frozen. This is regulatory malpractice of the highest order.

Time for a DEA Reckoning

We call on Congress, the White House, and the incoming DEA Administrator Terrance Cole-if he dares to break from the "good old boy" ranks-to:

Fire Thomas Prevoznik for gross negligence
Investigate Aarathi Haig for unethical conduct and possible New Jersey bar violations
Dissolve the DEA's control over cannabis research licensing
Transfer oversight to the FDA, where science-not sabotage-guides public health

"We followed the law. We built the facility. We got the FDA approvals. We even submitted a corrective action plan. And still, the DEA said no. That's not regulation-it's revenge."
- Duane Boise, CEO, MMJ BioPharma Cultivation

The DEA Can't Be Trusted to Do the Right Thing

If you think the DEA will suddenly become a friend to science, ask yourself:

Would you trust the arsonist to run the fire department?

The Verdict Isn't In Yet-But the Evidence Is Overwhelming

Terrance Cole may wear a new badge, but unless he breaks rank with the old guard, nothing will change. And if he doesn't act swiftly to grant MMJ's registration, he won't just be rubber-stamping a denial-he'll be rubber-stamping the DEA's obituary as a credible regulator.

America doesn't need another anti-marijuana crooner in a suit. It needs a reformer with courage.

Which one is Terrance Cole?

The next move is his.

MMJ is represented by attorney Megan Sheehan.

CONTACT:
Madison Hisey
MHisey@mmjih.com
203-231-8583

SOURCE: MMJ International Holdings



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/is-dea-administrator-terry-cole-just-another-anti-marijuana-crooner-i-1055480

© 2025 ACCESS Newswire
Hensoldt, Renk & Rheinmetall teuer
Rheinmetall, Renk und Hensoldt haben den Rüstungsboom der letzten Jahre dominiert, doch inzwischen sind diese Titel fundamental heillos überbewertet. KGVs jenseits der 60, KUVs über 4, und das in einem politisch fragilen Umfeld mit wackelnder Haushaltsdisziplin. Für späteinsteigende Anleger kann das teuer werden.

Doch es gibt Alternativen, die bislang unter dem Radar fliegen; solide bewertet, operativ stark und mit Nachholpotenzial.

In unserem kostenlosen Report zeigen wir dir, welche 3 Rüstungsunternehmen noch Potenzial haben und wie du von der zweiten Welle der Zeitenwende profitieren kannst, ohne sich an überhitzten Highflyer zu verbrennen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders vom weltweiten Aufrüsten profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.